Medication Monitor

Generic Name (Trade Name—Company)
August 19, 2011


(Tolnaftate-D—NexMed USA)
OTC antifungal approved


Treatment of jock itch, athlete’s foot, and ringworm

Apricus Biosciences announced that its NexMed USA subsidiary has received FDA clearance to market Tolnaftate-D, an OTC product that uses the company’s NextACT drug-delivery technology. This proprietary technology is designed to transiently loosen the tight junction between the cells of the sealed skin to allow more drug permeation, Apricus said in a news release.

The active ingredient, tolnaftate, is an already-marketed agent used for the treatment of jock itch, athlete's foot, and ringworm.